Quince Therapeutics (QNCX) investor relations material

Executive summary

• Annual meeting scheduled for June 11, 2026, with voting open until June 10, 2026, at 11:59 PM ET.

• Shareholders can access proxy materials online or request paper/email copies by May 28, 2026.

• Virtual meeting access and in-person voting options are available, with specific instructions for legal proxy requests.

Voting matters and shareholder proposals

• Election of June Bray as Class I director nominee to serve until the 2029 annual meeting.

• Approval sought for a reverse stock split at a ratio between one-for-ten and one-for-one-hundred.

• Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation for named executive officers.

• Approval to adjourn or postpone the meeting if further solicitation of proxies is needed.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director election and corporate actions.